Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Research · December 31, 2020

Effects of Empagliflozin on Renal Function in Patients With Heart Failure

The Lancet Diabetes & Endocrinology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Diabetes & Endocrinology
Effects of Empagliflozin on Estimated Extracellular Volume, Estimated Plasma Volume, and Measured Glomerular Filtration Rate in Patients With Heart Failure (Empire HF Renal): A Prespecified Substudy of a Double-Blind, Randomised, Placebo-Controlled Trial
Lancet Diabetes Endocrinol 2020 Dec 22;[EPub Ahead of Print], J Jensen, M Omar, C Kistorp, C Tuxen, I Gustafsson, L Køber, F Gustafsson, J Faber, ME Malik, EL Fosbøl, NE Bruun, JL Forman, LT Jensen, JE Møller, M Schou

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading